1 unchanged sentence
Market Information
−Removed: Our common stock has been listed on The Nasdaq Global Select Market under the symbol “SANA” since February 4, 2021.
+Added: Our common stock began trading on the Nasdaq Global Select Market under the symbol “SANA” on February 4, 2021.
Prior to that date, there was no public trading market for our common stock.
6 unchanged sentences
Stock Performance Graph
−Removed: The following performance graph and related information shall not be deemed to be “soliciting material” or to be “filed” with the SEC, for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, nor shall such information be incorporated by reference into any future filing under the Exchange Act or Securities Act of 1933, as amended, or the Securities Act, except to the extent that we specifically incorporate it by reference into such filing.
−Removed: The graph set forth below compares the cumulative total stockholder return on our shares of common stock between February 5, 2021 (the date of our initial public offering) and December 31, 2021, with the cumulative total return of (a) the Nasdaq Biotechnology Index and (b) the Nasdaq Composite Index, over the same period.
−Removed: This graph assumes the investment of $100 on February 5, 2021 in our common stock, the Nasdaq Biotechnology Index and the Nasdaq Composite Index and assumes the reinvestment of dividends, if any.
−Removed: The graph uses the closing sales price of our common stock of $39.12 per share on February 5, 2021 as the initial value of our common stock and not the initial offering price to the public of $25.00 per share.
+Added: The following stock performance graph and related information shall not be deemed to be “soliciting material” or to be “filed” with the SEC, for purposes of Section 18 of the Exchange Act, nor shall such information be incorporated by reference into any future filing under the Exchange Act or the Securities Act, except to the extent that we specifically incorporate it by reference into such filing.
+Added: The graph set forth below compares the cumulative total stockholder return on our shares of common stock between February 4, 2021 (the first day that our common stock began trading on the Nasdaq Global Select Market) and December 31, 2022, with the cumulative total return of (a) the Nasdaq Composite Index and (b) the Nasdaq Biotechnology Index, over the same period.
+Added: This graph assumes the investment of $100 on February 4, 2021 in our common stock, the Nasdaq Composite Index, and the Nasdaq Biotechnology Index, and assumes the reinvestment of dividends, if any.
+Added: The graph uses the closing sales price of our common stock of $35.10 per share on February 4, 2021 as the initial value of our common stock.
The comparisons shown in the graph below are based upon historical data.
The stock price performance included in this graph is not necessarily indicative of future stock price performance.
−Removed: *$100 invested on 2/5/21 in stock or index, including reinvestment of dividends.
+Added: *$100 invested on February 4, 2021 in stock or index, including reinvestment of dividends.
Fiscal year ending December 31
3 unchanged sentences
Use of Proceeds from our Initial Public Offering of Common Stock
−Removed: On February 8, 2021, we closed an initial public offering (IPO) and issued and sold 27,025,000 shares of our common stock, including 3,525,000 shares of common stock sold pursuant to the underwriters’ full exercise of their option to purchase additional shares, at a public offering price of $25.00 per share, for aggregate gross proceeds of $675.6 million.
+Added: On February 8, 2021, we closed our initial public offering (IPO) and issued and sold 27,025,000 shares of our common stock, including 3,525,000 shares of common stock sold pursuant to the underwriters’ full exercise of their option to purchase additional shares, at a public offering price of $25.00 per share, for aggregate net proceeds of $626.4 million.
All of the shares issued and sold in the IPO were registered under the Securities Act pursuant to a Registration Statement on Form S-1 (File No.
5 unchanged sentences
acted as joint bookrunning managers of the IPO and as representatives of the underwriters.
−Removed: No offering expenses were paid directly or indirectly to any of our directors or officers (or their associates) or persons owning 10.0% or more of any class of our equity securities or to any other affiliates.
+Added: No payment was made directly or indirectly to any of our directors or officers (or their associates) or persons owning 10.0% or more of any class of our equity securities or to any other affiliates.
We are holding a significant portion of the balance of the net proceeds from the offering in money market funds and short-term investments.
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.